Glauconix Biosciences Appoints W. Daniel Stamer to Technical Advisory Board

By

ALBANY, N.Y.—Glauconix Biosciences Inc., a specialty pharmaceutical company using patented technology to develop human 3D ocular tissues that mimic the fluid dynamics in the eye, has appointed W. Daniel Stamer, PhD, FARVO, to its scientific advisory board. Stamer, who is the president of the Association for Research in Vision and Ophthalmology and distinguished professor of ophthalmology at Duke University, will provide expert advice and insight in the areas of glaucoma research and in the validation of new technologies being developed by the company, according to an announcement Tuesday.

Glauconix is located in the SUNY Polytechnic Institute Campus in Albany and partner in the Center for Advanced Technology in Nanomaterials and Nanoelectronics.

“We are excited to announce the addition of Dr. Stamer to Glauconix Biosciences’ scientific advisory board,” Dr. Karen Torrejon, chairman and chief scientific officer, said in the announcement. “He has pioneered groundbreaking studies that have enhanced our understanding on glaucoma pathophysiology.”

She added, “Our focus has always been to mitigate the translational gap between preclinical and clinical studies in the field of ophthalmology, and we believe that the guidance and expertise that Dr. Stamer brings will be instrumental as we continue to build on our mission to develop technologies that will enhance patients’ quality of life and reduce economic burden to society caused by devastating eye diseases.”

“While not officially part of the advisory board, I have been collaborating with Dr. Torrejon at Glauconix for several years, helping to optimize her cutting-edge screening platform,” Stamer said in the announcement. “This platform is the best model for the resistance-generating region in the conventional outflow pathway that I have seen so far.”